25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

NEUP (Neuphoria Therapeutics Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Neuphoria Therapeutics Inc together

I guess you are interested in Neuphoria Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Neuphoria Therapeutics Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Neuphoria Therapeutics Inc’s Price Targets

I'm going to help you getting a better view of Neuphoria Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Neuphoria Therapeutics Inc

I send you an email if I find something interesting about Neuphoria Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Neuphoria Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Neuphoria Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.12
Expected worth in 1 year
$-0.14
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-0.25
Return On Investment
-1.3%

For what price can you sell your share?

Current Price per Share
$19.00
Expected price per share
$15.14 - $27.96
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Neuphoria Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$19.00
Intrinsic Value Per Share
$-1.15 - $0.54
Total Value Per Share
$-1.03 - $0.66

2.2. Growth of Neuphoria Therapeutics Inc (5 min.)




Is Neuphoria Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$17.4m$22m-$4.5m-25.8%

How much money is Neuphoria Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$15.4m-$21.3m$5.8m38.0%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Neuphoria Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Neuphoria Therapeutics Inc?

Welcome investor! Neuphoria Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Neuphoria Therapeutics Inc.

First you should know what it really means to hold a share of Neuphoria Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Neuphoria Therapeutics Inc is $19.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Neuphoria Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Neuphoria Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.12. Based on the TTM, the Book Value Change Per Share is $-0.06 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.17 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Neuphoria Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.10-0.5%-0.10-0.5%-0.17-0.9%-0.14-0.7%-0.12-0.7%-0.21-1.1%
Usd Book Value Change Per Share-0.06-0.3%-0.06-0.3%-0.17-0.9%-0.14-0.8%-0.03-0.2%-0.11-0.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.06-0.3%-0.06-0.3%-0.17-0.9%-0.14-0.8%-0.03-0.2%-0.11-0.6%
Usd Price Per Share0.77-0.77-2.20-3.32-1.99-1.00-
Price to Earnings Ratio-7.42--7.42--12.59--24.23--14.54--7.27-
Price-to-Total Gains Ratio-12.16--12.16--13.15--19.91--19.91--19.91-
Price to Book Ratio6.57-6.57-12.23-12.98-7.79-3.89-
Price-to-Total Gains Ratio-12.16--12.16--13.15--19.91--19.91--19.91-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share19
Number of shares52
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.06-0.03
Usd Total Gains Per Share-0.06-0.03
Gains per Quarter (52 shares)-3.28-1.75
Gains per Year (52 shares)-13.12-7.01
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-13-230-7-17
20-26-360-14-24
30-39-490-21-31
40-52-620-28-38
50-66-750-35-45
60-79-880-42-52
70-92-1010-49-59
80-105-1140-56-66
90-118-1270-63-73
100-131-1400-70-80

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%1.025.00.03.8%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%2.08.00.020.0%10.016.00.038.5%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.026.00.0%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%2.08.00.020.0%10.016.00.038.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Neuphoria Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.063-0.0630%-0.167+165%-0.144+129%-0.034-47%-0.110+74%
Book Value Per Share--0.1170.1170%0.180-35%0.215-46%0.277-58%0.429-73%
Current Ratio--3.4463.4460%4.866-29%6.924-50%6.976-51%5.119-33%
Debt To Asset Ratio--0.3670.3670%0.229+60%0.242+52%0.296+24%0.446-18%
Debt To Equity Ratio--0.5810.5810%0.298+95%0.342+70%0.577+1%1.107-48%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--117346017.248117346017.2480%274818821.600-57%399268208.856-71%399268208.856-71%399268208.856-71%
Eps---0.103-0.1030%-0.175+69%-0.137+32%-0.124+20%-0.206+99%
Ev To Ebitda Ratio---6.849-6.8490%-13.151+92%-25.421+271%-25.421+271%-25.421+271%
Free Cash Flow Per Share---0.098-0.0980%-0.120+22%-0.117+19%-0.099+1%-0.138+41%
Free Cash Flow To Equity Per Share--0.0030.0030%-0.088+3182%-0.018+721%0.017-83%0.020-86%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.541----------
Intrinsic Value_10Y_min---1.149----------
Intrinsic Value_1Y_max---0.066----------
Intrinsic Value_1Y_min---0.134----------
Intrinsic Value_3Y_max---0.108----------
Intrinsic Value_3Y_min---0.388----------
Intrinsic Value_5Y_max---0.038----------
Intrinsic Value_5Y_min---0.625----------
Market Cap30918320.000-272%114897017.248114897017.2480%269268159.600-57%390830660.189-71%234498396.114-51%117249198.057-2%
Net Profit Margin----0%-0%-0.8240%-32.4130%-17.7470%
Operating Margin----0%-0%-0.8300%-19.8870%-11.5700%
Operating Ratio----0%-0%2.183-100%43.321-100%24.408-100%
Pb Ratio162.734+96%6.5696.5690%12.234-46%12.979-49%7.788-16%3.894+69%
Pe Ratio-183.719-2377%-7.416-7.4160%-12.593+70%-24.225+227%-14.535+96%-7.268-2%
Price Per Share19.000+96%0.7670.7670%2.200-65%3.319-77%1.991-61%0.996-23%
Price To Free Cash Flow Ratio-193.870-2377%-7.826-7.8260%-18.395+135%-26.298+236%-15.779+102%-7.889+1%
Price To Total Gains Ratio-301.217-2377%-12.160-12.1600%-13.149+8%-19.910+64%-19.910+64%-19.910+64%
Quick Ratio--3.3263.3260%4.575-27%6.642-50%6.570-49%4.705-29%
Return On Assets---0.560-0.5600%-0.749+34%-0.547-2%-0.402-28%-0.309-45%
Return On Equity---0.886-0.8860%-0.971+10%-0.747-16%-0.597-33%-0.610-31%
Total Gains Per Share---0.063-0.0630%-0.167+165%-0.144+129%-0.034-47%-0.110+74%
Usd Book Value--17490000.00017490000.0000%22010563.000-21%26217148.333-33%24625462.800-29%23527170.000-26%
Usd Book Value Change Per Share---0.063-0.0630%-0.167+165%-0.144+129%-0.034-47%-0.110+74%
Usd Book Value Per Share--0.1170.1170%0.180-35%0.215-46%0.277-58%0.429-73%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--117346017.248117346017.2480%274818821.600-57%399268208.856-71%399268208.856-71%399268208.856-71%
Usd Eps---0.103-0.1030%-0.175+69%-0.137+32%-0.124+20%-0.206+99%
Usd Free Cash Flow---14681000.000-14681000.0000%-14637720.0000%-14761861.333+1%-10527613.400-28%-8877937.700-40%
Usd Free Cash Flow Per Share---0.098-0.0980%-0.120+22%-0.117+19%-0.099+1%-0.138+41%
Usd Free Cash Flow To Equity Per Share--0.0030.0030%-0.088+3182%-0.018+721%0.017-83%0.020-86%
Usd Market Cap30918320.000-272%114897017.248114897017.2480%269268159.600-57%390830660.189-71%234498396.114-51%117249198.057-2%
Usd Price Per Share19.000+96%0.7670.7670%2.200-65%3.319-77%1.991-61%0.996-23%
Usd Profit---15492166.000-15492166.0000%-21381677.000+38%-17280769.000+12%-12653566.400-18%-11905719.800-23%
Usd Revenue----0%-0%2018440.667-100%1403091.400-100%2688146.600-100%
Usd Total Gains Per Share---0.063-0.0630%-0.167+165%-0.144+129%-0.034-47%-0.110+74%
 EOD+3 -5MRQTTM+0 -0YOY+17 -153Y+17 -175Y+9 -2510Y+15 -19

3.3 Fundamental Score

Let's check the fundamental score of Neuphoria Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-183.719
Price to Book Ratio (EOD)Between0-1162.734
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.326
Current Ratio (MRQ)Greater than13.446
Debt to Asset Ratio (MRQ)Less than10.367
Debt to Equity Ratio (MRQ)Less than10.581
Return on Equity (MRQ)Greater than0.15-0.886
Return on Assets (MRQ)Greater than0.05-0.560
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Neuphoria Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5070.314
Ma 20Greater thanMa 5013.628
Ma 50Greater thanMa 10011.128
Ma 100Greater thanMa 2009.107
OpenGreater thanClose18.400
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Neuphoria Therapeutics Inc

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders; and Nav1.7/1.8 inhibitors which is in preclinical trial for the potential treatment of chronic pain without the liability of addiction associated with opioid treatment. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.

Fundamental data was last updated by Penke on 2025-10-04 06:44:07.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Neuphoria Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Neuphoria Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Neuphoria Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-3,241.3%+3,241.3%
5Y-3,241.3%10Y-1,774.7%-1,466.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--68.9%+68.9%
TTM--157.5%+157.5%
YOY--189.1%+189.1%
3Y-82.4%-262.3%+179.9%
5Y-3,241.3%-336.5%-2,904.8%
10Y-1,774.7%-471.4%-1,303.3%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Neuphoria Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Neuphoria Therapeutics Inc to theΒ Biotechnology industry mean.
  • -56.0% Return on Assets means thatΒ Neuphoria Therapeutics Inc generatedΒ $-0.56 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Neuphoria Therapeutics Inc:

  • The MRQ is -56.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -56.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-56.0%TTM-56.0%0.0%
TTM-56.0%YOY-74.9%+18.8%
TTM-56.0%5Y-40.2%-15.9%
5Y-40.2%10Y-30.9%-9.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-56.0%-11.9%-44.1%
TTM-56.0%-11.8%-44.2%
YOY-74.9%-11.1%-63.8%
3Y-54.7%-12.0%-42.7%
5Y-40.2%-11.8%-28.4%
10Y-30.9%-13.9%-17.0%
4.3.1.3. Return on Equity

Shows how efficient Neuphoria Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Neuphoria Therapeutics Inc to theΒ Biotechnology industry mean.
  • -88.6% Return on Equity means Neuphoria Therapeutics Inc generated $-0.89Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Neuphoria Therapeutics Inc:

  • The MRQ is -88.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -88.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-88.6%TTM-88.6%0.0%
TTM-88.6%YOY-97.1%+8.6%
TTM-88.6%5Y-59.7%-28.9%
5Y-59.7%10Y-61.0%+1.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-88.6%-14.1%-74.5%
TTM-88.6%-14.7%-73.9%
YOY-97.1%-15.3%-81.8%
3Y-74.7%-16.7%-58.0%
5Y-59.7%-17.1%-42.6%
10Y-61.0%-19.7%-41.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Neuphoria Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Neuphoria Therapeutics Inc is operatingΒ .

  • Measures how much profit Neuphoria Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Neuphoria Therapeutics Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Neuphoria Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-1,988.7%+1,988.7%
5Y-1,988.7%10Y-1,157.0%-831.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--153.1%+153.1%
TTM--265.6%+265.6%
YOY--242.6%+242.6%
3Y-83.0%-247.2%+164.2%
5Y-1,988.7%-326.3%-1,662.4%
10Y-1,157.0%-487.4%-669.6%
4.3.2.2. Operating Ratio

Measures how efficient Neuphoria Therapeutics Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Neuphoria Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y43.321-43.321
5Y43.32110Y24.408+18.912
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.861-1.861
TTM-2.729-2.729
YOY-2.820-2.820
3Y2.1833.542-1.359
5Y43.3214.614+38.707
10Y24.4086.171+18.237
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Neuphoria Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Neuphoria Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 3.45Β means the company has $3.45 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Neuphoria Therapeutics Inc:

  • The MRQ is 3.446. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.446. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.446TTM3.4460.000
TTM3.446YOY4.866-1.420
TTM3.4465Y6.976-3.530
5Y6.97610Y5.119+1.857
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4463.414+0.032
TTM3.4463.605-0.159
YOY4.8664.048+0.818
3Y6.9244.419+2.505
5Y6.9765.731+1.245
10Y5.1196.121-1.002
4.4.3.2. Quick Ratio

Measures if Neuphoria Therapeutics Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Neuphoria Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 3.33Β means the company can pay off $3.33 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Neuphoria Therapeutics Inc:

  • The MRQ is 3.326. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.326. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.326TTM3.3260.000
TTM3.326YOY4.575-1.249
TTM3.3265Y6.570-3.245
5Y6.57010Y4.705+1.865
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3262.783+0.543
TTM3.3263.128+0.198
YOY4.5753.806+0.769
3Y6.6424.322+2.320
5Y6.5705.680+0.890
10Y4.7056.495-1.790
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Neuphoria Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Neuphoria Therapeutics IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Neuphoria Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.37Β means that Neuphoria Therapeutics Inc assets areΒ financed with 36.7% credit (debt) and the remaining percentage (100% - 36.7%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Neuphoria Therapeutics Inc:

  • The MRQ is 0.367. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.367. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.367TTM0.3670.000
TTM0.367YOY0.229+0.138
TTM0.3675Y0.296+0.071
5Y0.29610Y0.446-0.150
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3670.346+0.021
TTM0.3670.364+0.003
YOY0.2290.337-0.108
3Y0.2420.350-0.108
5Y0.2960.349-0.053
10Y0.4460.380+0.066
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Neuphoria Therapeutics Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Neuphoria Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 58.1% means that company has $0.58 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Neuphoria Therapeutics Inc:

  • The MRQ is 0.581. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.581. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.581TTM0.5810.000
TTM0.581YOY0.298+0.283
TTM0.5815Y0.577+0.004
5Y0.57710Y1.107-0.530
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5810.402+0.179
TTM0.5810.448+0.133
YOY0.2980.436-0.138
3Y0.3420.471-0.129
5Y0.5770.469+0.108
10Y1.1070.517+0.590
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Neuphoria Therapeutics Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Neuphoria Therapeutics Inc to theΒ Biotechnology industry mean.
  • A PE ratio of -7.42 means the investor is paying $-7.42Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Neuphoria Therapeutics Inc:

  • The EOD is -183.719. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.416. Based on the earnings, the company is expensive. -2
  • The TTM is -7.416. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-183.719MRQ-7.416-176.303
MRQ-7.416TTM-7.4160.000
TTM-7.416YOY-12.593+5.177
TTM-7.4165Y-14.535+7.119
5Y-14.53510Y-7.268-7.268
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-183.719-2.952-180.767
MRQ-7.416-2.328-5.088
TTM-7.416-2.657-4.759
YOY-12.593-3.622-8.971
3Y-24.225-3.737-20.488
5Y-14.535-5.857-8.678
10Y-7.268-6.949-0.319
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Neuphoria Therapeutics Inc:

  • The EOD is -193.870. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.826. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.826. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-193.870MRQ-7.826-186.044
MRQ-7.826TTM-7.8260.000
TTM-7.826YOY-18.395+10.569
TTM-7.8265Y-15.779+7.952
5Y-15.77910Y-7.889-7.889
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-193.870-3.656-190.214
MRQ-7.826-2.911-4.915
TTM-7.826-3.682-4.144
YOY-18.395-4.243-14.152
3Y-26.298-5.190-21.108
5Y-15.779-8.391-7.388
10Y-7.889-9.883+1.994
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Neuphoria Therapeutics Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 6.57 means the investor is paying $6.57Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Neuphoria Therapeutics Inc:

  • The EOD is 162.734. Based on the equity, the company is expensive. -2
  • The MRQ is 6.569. Based on the equity, the company is overpriced. -1
  • The TTM is 6.569. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD162.734MRQ6.569+156.164
MRQ6.569TTM6.5690.000
TTM6.569YOY12.234-5.664
TTM6.5695Y7.788-1.218
5Y7.78810Y3.894+3.894
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD162.7342.519+160.215
MRQ6.5692.059+4.510
TTM6.5692.220+4.349
YOY12.2342.464+9.770
3Y12.9792.641+10.338
5Y7.7883.760+4.028
10Y3.8944.482-0.588
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets27,649
Total Liabilities10,159
Total Stockholder Equity17,490
 As reported
Total Liabilities 10,159
Total Stockholder Equity+ 17,490
Total Assets = 27,649

Assets

Total Assets27,649
Total Current Assets13,194
Long-term Assets14,455
Total Current Assets
Cash And Cash Equivalents 12,608
Net Receivables 127
Other Current Assets 459
Total Current Assets  (as reported)13,194
Total Current Assets  (calculated)13,194
+/-0
Long-term Assets
Property Plant Equipment 219
Goodwill 8,690
Intangible Assets 5,468
Long-term Assets Other 78
Long-term Assets  (as reported)14,455
Long-term Assets  (calculated)14,455
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities3,829
Long-term Liabilities6,330
Total Stockholder Equity17,490
Total Current Liabilities
Short-term Debt 155
Short Long Term Debt 33
Accounts payable 2,244
Other Current Liabilities 1,430
Total Current Liabilities  (as reported)3,829
Total Current Liabilities  (calculated)3,862
+/- 33
Long-term Liabilities
Capital Lease Obligations 240
Long-term Liabilities Other 591
Long-term Liabilities  (as reported)6,330
Long-term Liabilities  (calculated)830
+/- 5,500
Total Stockholder Equity
Retained Earnings -177,977
Accumulated Other Comprehensive Income -3,014
Other Stockholders Equity 198,481
Total Stockholder Equity (as reported)17,490
Total Stockholder Equity (calculated)17,490
+/-0
Other
Cash and Short Term Investments 12,608
Common Stock Shares Outstanding 149,801
Liabilities and Stockholders Equity 27,649
Net Debt -12,335
Net Invested Capital 17,523
Net Working Capital 9,365
Property Plant and Equipment Gross 265
Short Long Term Debt Total 273



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-301999-06-30
> Total Assets 
142
3,169
5,526
8,917
8,470
10,460
13,000
14,629
26,142
27,089
19,954
26,783
36,668
31,830
48,925
61,254
53,024
65,724
64,608
47,797
37,580
23,680
40,770
44,927
28,563
27,649
27,64928,56344,92740,77023,68037,58047,79764,60865,72453,02461,25448,92531,83036,66826,78319,95427,08926,14214,62913,00010,4608,4708,9175,5263,169142
   > Total Current Assets 
142
2,799
5,085
4,973
4,180
6,272
7,197
3,828
11,836
8,473
4,752
11,810
26,597
22,247
28,031
37,206
29,055
43,377
41,864
26,387
17,601
5,726
23,237
28,762
13,327
13,194
13,19413,32728,76223,2375,72617,60126,38741,86443,37729,05537,20628,03122,24726,59711,8104,7528,47311,8363,8287,1976,2724,1804,9735,0852,799142
       Cash And Cash Equivalents 
57
312
1
4,837
4,090
6,085
6,866
3,509
10,874
6,009
3,839
10,719
17,156
17,742
20,490
9,886
20,370
33,941
32,946
18,314
9,795
3,145
21,413
23,090
12,103
12,608
12,60812,10323,09021,4133,1459,79518,31432,94633,94120,3709,88620,49017,74217,15610,7193,8396,00910,8743,5096,8666,0854,0904,837131257
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
36
0
0
422
411
423
404
385
0
327
0
0
0
000327038540442341142200360000000000000
       Net Receivables 
0
44
43
56
19
95
108
180
288
2,215
626
720
9,030
421
644
19,527
816
8,217
7,602
524
621
41
193
4,667
426
127
1274264,667193416215247,6028,21781619,5276444219,0307206262,21528818010895195643440
       Other Current Assets 
85
2,444
5,041
80
71
92
199
106
590
174
188
275
366
3,945
6,807
7,715
7,133
481
566
6,786
6,335
2,540
1,631
1,005
797
459
4597971,0051,6312,5406,3356,7865664817,1337,7156,8073,9453662751881745901061999271805,0412,44485
   > Long-term Assets 
0
370
442
3,944
4,290
4,189
5,803
10,802
14,305
18,615
15,203
14,973
10,071
9,583
20,895
24,048
23,969
22,347
22,744
21,410
19,979
17,954
17,534
16,166
15,236
14,455
14,45515,23616,16617,53417,95419,97921,41022,74422,34723,96924,04820,8959,58310,07114,97315,20318,61514,30510,8025,8034,1894,2903,9444423700
       Property Plant Equipment 
0
260
369
3,888
4,252
4,179
4,311
4,189
7,318
8,245
6,762
6,720
324
791
769
780
2,647
2,117
2,012
2,016
1,756
725
654
464
333
219
2193334646547251,7562,0162,0122,1172,6477807697913246,7206,7628,2457,3184,1894,3114,1794,2523,8883692600
       Goodwill 
0
0
0
0
0
0
1,491
1,615
1,804
4,925
4,155
4,375
5,502
5,268
4,698
8,933
8,045
7,947
9,424
9,160
8,937
8,845
9,317
8,852
8,694
8,690
8,6908,6948,8529,3178,8458,9379,1609,4247,9478,0458,9334,6985,2685,5024,3754,1554,9251,8041,6151,491000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
119
0
0
0
0001190000000000000000000000
       Intangible Assets 
0
110
72
56
38
10
1
4,997
5,182
5,445
4,285
3,878
4,245
3,451
15,427
14,335
12,983
11,996
11,013
9,952
9,016
8,085
7,473
6,768
6,130
5,468
5,4686,1306,7687,4738,0859,0169,95211,01311,99612,98314,33515,4273,4514,2453,8784,2855,4455,1824,9971103856721100
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000
> Total Liabilities 
506
147
328
3,293
3,946
4,216
4,858
6,507
6,889
6,492
4,867
5,141
5,995
5,325
11,137
19,058
28,506
34,036
33,521
35,340
25,185
14,966
5,008
5,777
6,552
10,159
10,1596,5525,7775,00814,96625,18535,34033,52134,03628,50619,05811,1375,3255,9955,1414,8676,4926,8896,5074,8584,2163,9463,293328147506
   > Total Current Liabilities 
473
104
302
475
829
982
1,552
1,990
3,064
2,919
2,252
2,750
5,857
4,573
5,551
8,738
10,512
8,503
10,673
9,759
9,666
5,684
1,774
2,308
2,739
3,829
3,8292,7392,3081,7745,6849,6669,75910,6738,50310,5128,7385,5514,5735,8572,7502,2522,9193,0641,9901,552982829475302104473
       Short-term Debt 
134
0
0
72
343
355
273
307
459
547
427
533
3,022
750
621
742
4,188
2,893
6,529
4,286
5,919
4,090
131
110
114
155
1551141101314,0905,9194,2866,5292,8934,1887426217503,0225334275474593072733553437200134
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33
33
3333000000000000000000000000
       Accounts payable 
339
90
78
194
236
366
730
799
1,798
1,650
917
1,177
1,451
2,038
2,986
2,508
3,017
1,966
1,460
2,650
842
867
773
1,071
1,439
2,244
2,2441,4391,0717738678422,6501,4601,9663,0172,5082,9862,0381,4511,1779171,6501,7987997303662361947890339
       Other Current Liabilities 
0
13
187
140
236
226
430
722
714
491
824
981
1,333
1,766
1,910
2,411
3,250
3,594
2,669
2,759
2,747
727
870
1,127
1,186
1,430
1,4301,1861,1278707272,7472,7592,6693,5943,2502,4111,9101,7661,333981824491714722430226236140187130
   > Long-term Liabilities 
33
43
26
2,819
3,117
3,234
3,306
4,517
3,825
3,574
2,614
2,391
139
752
5,587
10,320
17,994
25,533
22,848
25,581
15,519
9,282
3,235
3,468
3,814
6,330
6,3303,8143,4683,2359,28215,51925,58122,84825,53317,99410,3205,5877521392,3912,6143,5743,8254,5173,3063,2343,1172,819264333
> Total Stockholder Equity
-364
3,022
5,198
5,624
4,525
6,244
8,143
8,123
19,252
20,596
15,087
21,643
30,673
26,505
37,788
42,197
24,518
31,688
31,087
12,457
12,395
8,714
35,762
39,151
22,011
17,490
17,49022,01139,15135,7628,71412,39512,45731,08731,68824,51842,19737,78826,50530,67321,64315,08720,59619,2528,1238,1436,2444,5255,6245,1983,022-364
   Common Stock
251
4,419
8,066
10,752
13,722
18,286
25,004
28,226
44,813
53,672
48,398
63,838
93,721
89,890
101,584
105,185
85,897
100,362
103,385
99,326
101,510
101,801
142,897
149,755
0
0
00149,755142,897101,801101,51099,326103,385100,36285,897105,185101,58489,89093,72163,83848,39853,67244,81328,22625,00418,28613,72210,7528,0664,419251
   Retained Earnings -177,977-162,485-119,219-115,736-102,304-98,654-96,491-83,143-77,050-66,397-65,545-66,459-64,293-63,791-44,903-36,012-36,126-27,969-20,425-16,666-12,042-9,197-5,128-2,867-1,397-615
   Capital Surplus 00000000000000000000000000
   Treasury Stock00000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
187,554
198,481
198,481187,554000000000000000000000000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-06-30. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-17,892
Operating Income-17,892-17,892
 
Operating Expense (+$)
Research Development9,418
Selling General Administrative8,475
Selling And Marketing Expenses-
Operating Expense17,89217,892
 
Net Interest Income (+$)
Interest Income220
Interest Expense--
Other Finance Cost-0
Net Interest Income220
 
Pretax Income (+$)
Operating Income-17,892
Net Interest Income220
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-15,579-20,205
EBIT - interestExpense = -17,797
-15,579
-15,492
Interest Expense-
Earnings Before Interest and Taxes (EBIT)-17,797-15,579
Earnings Before Interest and Taxes (EBITDA)-17,134
 
After tax Income (+$)
Income Before Tax-15,579
Tax Provision--87
Net Income From Continuing Ops-15,492-15,492
Net Income-15,492
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses17,892
Total Other Income/Expenses Net2,313-220
 

Technical Analysis of Neuphoria Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Neuphoria Therapeutics Inc. The general trend of Neuphoria Therapeutics Inc is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Neuphoria Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Neuphoria Therapeutics Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Neuphoria Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 20.04 < 26.28 < 27.96.

The bearish price targets are: 15.72 > 15.60 > 15.14.

Know someone who trades $NEUP? Share this with them.πŸ‘‡

Neuphoria Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Neuphoria Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Neuphoria Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Neuphoria Therapeutics Inc. The current macd is 2.16763052.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Neuphoria Therapeutics Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Neuphoria Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Neuphoria Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Neuphoria Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartNeuphoria Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Neuphoria Therapeutics Inc. The current adx is 35.07.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Neuphoria Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Neuphoria Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Neuphoria Therapeutics Inc. The current sar is 13.05.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Neuphoria Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Neuphoria Therapeutics Inc. The current rsi is 70.31. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Neuphoria Therapeutics Inc Daily Relative Strength Index (RSI) ChartNeuphoria Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Neuphoria Therapeutics Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Neuphoria Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Neuphoria Therapeutics Inc Daily Stochastic Oscillator ChartNeuphoria Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Neuphoria Therapeutics Inc. The current cci is 125.35.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Neuphoria Therapeutics Inc Daily Commodity Channel Index (CCI) ChartNeuphoria Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Neuphoria Therapeutics Inc. The current cmo is 45.57.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Neuphoria Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartNeuphoria Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Neuphoria Therapeutics Inc. The current willr is -20.19111066.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Neuphoria Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Neuphoria Therapeutics Inc Daily Williams %R ChartNeuphoria Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Neuphoria Therapeutics Inc. The current atr is 1.89097695.

Neuphoria Therapeutics Inc Daily Average True Range (ATR) ChartNeuphoria Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Neuphoria Therapeutics Inc. The current obv is 68,261,842.

Neuphoria Therapeutics Inc Daily On-Balance Volume (OBV) ChartNeuphoria Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Neuphoria Therapeutics Inc. The current mfi is 83.61.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Neuphoria Therapeutics Inc Daily Money Flow Index (MFI) ChartNeuphoria Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Neuphoria Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-05-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-23ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-07-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-29MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-08-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-08-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-08-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-08-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-09-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-09-09BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-09-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-10-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-07STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-10-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-10-09STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Neuphoria Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Neuphoria Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5070.314
Ma 20Greater thanMa 5013.628
Ma 50Greater thanMa 10011.128
Ma 100Greater thanMa 2009.107
OpenGreater thanClose18.400
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Neuphoria Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Neuphoria Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Neuphoria Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Neuphoria Therapeutics Inc

I send you an email if I find something interesting about Neuphoria Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Neuphoria Therapeutics Inc.

Receive notifications about Neuphoria Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.